Cue Biopharma Study result
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Morning everyone, and welcome to the Cue Biopharma conference call on the CUE-221 CSU phase II top line results. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press star one one on your telephone. You will then hear an automated message advising that your hand is raised. I would now like to turn the call over to Agnes Lee, Chief Investor Relations and Communications Officer at Cue Biopharma.
Please go ahead, Agnes. Good morning, and thank you for joining us today.
Before we begin our formal comments, let me remind you that during today's webcast, we will be making forward-looking statements that represent the company's intentions, expectations, or beliefs concerning future events. These statements represent our views as of this date, are subject to risks and uncertainties, and should not be relied upon as representing our views or of any subsequent date in the future. As a reminder, this call is being recorded, and a replay will be made available on the investor section of Cue Biopharma's website following the conclusion of the event. With me on the call today are Dr. Shao-Lee Lin, our President and Chief Executive Officer, and Dr. Dominique Borie, our Chief Medical Officer and Head of R&D. Dr. Lin will open the call and then hand off to Dr. Borie to walk through the study data.
Dr. Lin will then close our prepared remarks, and we will take questions. With that, I will now turn the call over to Xiaoli.
Thank you, Agnes, and good morning, everyone. Thank you for joining us. Today, we are reporting results from the phase II study of CUE-221 in the chronic spontaneous urticaria, or CSU. We're pleased to share that the study results were positive and that we will be reviewing together those top-line clinical results with you today. The key takeaway is that CUE-221 met its primary and key secondary endpoints in a manner that reinforces our enthusiasm for the precision-engineered unique dual mechanism of action of CUE-221, and its potential to offer clinically meaningful and differentiated benefit in IgE-mediated disease. Slide 3 summarizes the salient findings from the study. The study demonstrated robust, durable, and dose-responsive clinical effects.
The primary endpoint of complete resolution of hives, or HSS7 equals 0 at week 12, was met with the treatment effect further increasing past the final dose at week 16 to its peak at week 22. The key secondary endpoint of complete response, or UAS7 equals 0, was statistically significant in the high-dose group, further supporting the clinically meaningful impact of CUE-221. These results were achieved in a context of a favorable safety and tolerability profile. Of note, for the CUE-221 high-dose group, both the complete resolution of hives and the overall complete response persisted for 12 weeks or a full quarter, and on the order of five half-lives after the last dose.
This was not seen for the lower doses or for omalizumab, despite a comparable dose level, highlighting a fundamental clinical difference consistent with the biological design differences between the two drugs and supporting the concept that CUE-221 has the potential to be a disease-modifying therapy. This marked difference observed off drug at week 28 relative to omalizumab provides our first clinical evidence supportive of the CUE-221 engineered dual mechanism of action that includes not only blocking of the IgE-mediated allergic cascade, like omalizumab, but also supports the clinical potential of downregulation of new IgE production unique to the design of CUE-221. Additional PK and IgE data are of interest, and while not available today, will be the subject of further modeling analyses and future presentations at upcoming medical meetings.
Based on this demonstrated potential for differentiated clinical efficacy in CSU and the potential to develop a new tool to target disease modification and the concept of functional cure for IgE-mediated diseases, we are more than excited to now plan both a phase II-B/III next study in CSU as well as a phase II study for food allergy. I will now hand the call over to Dominique Borie, our Chief Medical Officer and Head of Research Development.
Dominique? Thank you, Xiaoli. Let me take a couple of minutes to quickly walk the audience through the science behind CUE-221.
First, reminding ourselves that IgE drives allergic disease by engaging two receptors. The high-affinity receptor, shown here on the left, through which IgE and the allergen will trigger degranulation and allergic symptoms. And the low-affinity receptor, also known as CD23, shown on the right, which is expressed on the surface of B cells and has an important role too, as when bound by IgE, it triggers a natural negative feedback loop that results in reduced IgE synthesis. On slide 5, CUE-221 was designed to block IgE binding to the high-affinity receptor, and in doing so, provides potent IgE neutralization or IgE blocking.
CUE-221 high binding affinity for IgE, shown here on the left, supports a greater potency at preventing IgE-mediated cell degranulation over omalizumab, as shown on the graph on the right. On slide 6, on the flip side, CUE-221 was also designed to preserve IgE binding to CD23. This was achieved through selecting binding sites on IgE that are distant from the IgE region that engages CD23, whereas the binding site on IgE for omalizumab and its analog, RPT904, is the same as shown on the right and overlaps with the CD23 binding site, and therefore does not allow the drug IgE complexes to bind CD23.
On slide 7, as the result of the difference in engineering, increasing concentrations of IgE in complex with CUE-221 can bind to the CD23 receptor, as shown by the orange curve on the right, whereas no binding at all was measured with IgE in complex with omalizumab, as shown by the gray triangles. On slide 8, the biological impact of preserved binding to CD23 was demonstrated both at the mRNA and at the protein level, where addition of CUE-221 resulted in a significant reduction in IgE synthesis, shown by the orange bars, that was not observed for omalizumab, in gray bars, indicating that omalizumab in complex with IgE cannot block new IgE production. On slide 9, it was therefore very exciting to test the clinical impact of these fundamental biological differences in the context of a phase II randomized, double-blind, and placebo-controlled study.
An omalizumab arm was included for comparative efficacy and safety, but no formal statistical testing was planned. The study enrolled participants with moderate to severe chronic spontaneous urticaria, or CSU, inadequately controlled with H1 antihistamines. Patients were randomized to either one of CUE-221 dose groups at 1, 2, or 4 milligrams per kilogram, administered sub-Q, or to omalizumab at the registered dose or to placebo. All patients received sub-Q injections every 4 weeks, and the primary endpoint was assessed at week 12 and measured the rate of complete resolution of hives, or HSS7 score of 0. This endpoint leverages an objective assessment of the number of hives, which is carried out by the physician, and achievement requires all clear skin or no hives.
The final dose in the study was administered on week 16 for all groups, and after which patients were monitored off drug for 20 weeks through week 36. Slide 10 shows the subject's disposition for the trial. Two subjects were randomized but not dosed, one in the 4 milligram per kilogram group and one in the omalizumab group. The dropout rates are in range with expectation for a clinical trial of that duration, further considering the 5-month observation period of drugs. This study was analyzed using a modified intent-to-treat approach. The two subjects who were not dosed were not part of that analysis, but all other subjects were included in the modified intent-to-treat analysis. On slide 11, the baseline characteristics were overall well-balanced across groups.
Disease duration ranged approximately for 4 to 6 years across groups, and mean baseline Urticaria Activity Score 7, or UAS7, were in the 28-plus point range, indicative of severe disease activity. On slide 12, getting to the results, we are excited to report that the study primary endpoint was met. Complete resolution of hives, HSS7 equals 0 at week 12, was significantly higher than placebo for all dose groups in a dose-responsive manner with a high P value of less than 0.005 for the high dose group. On slide 13, the key secondary endpoint of complete response for UAS7 equals 0 was also met, and the difference versus placebo was statistically significant for the high dose group.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
7 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
